Related Experiment Video
Updated: Jul 6, 2025

Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding
Published on: June 9, 2017
G protein-coupled receptors and obesity
1Cardiovascular and Metabolic Disease, Johnson & Johnson Innovative Medicine Research & Development, Spring House, PA, United States.
New anti-obesity medications targeting G protein-coupled receptors (GPCRs) offer significant weight loss and cardiovascular benefits. The development of therapies like glucagon like peptide 1 receptor agonists (GLP-1RAs) is transforming obesity management.
Area of Science:
- Pharmacology
- Endocrinology
- Cardiology
Background:
- G protein-coupled receptors (GPCRs) are crucial drug targets for chronic diseases like obesity and diabetes.
- Obesity is a complex condition linked to type 2 diabetes, heart disease, and cancer.
- Semaglutide, a glucagon like peptide 1 receptor agonist (GLP-1RA), marks a significant advancement in anti-obesity pharmacotherapy.
Purpose of the Study:
- To review the evolving therapeutic landscape for GPCR-targeted anti-obesity medications.
- To highlight the impact of recent drug approvals and emerging treatment strategies.
- To discuss the commercial implications and future directions in obesity pharmacotherapy.
Main Methods:
- Review of recent clinical trial data and regulatory approvals for anti-obesity medications.
- Analysis of pharmacological advancements in targeting GPCRs.
- Market analysis of the obesity drug sector.
Main Results:
- Semaglutide, a GLP-1RA, achieved double-digit weight loss (≥10%) and demonstrated cardiovascular benefits.
- The success of GLP-1RAs has stimulated new market entrants and investment.
- Progress includes dual GIP/GLP-1 agonists, oral GLP-1 formulations, and small molecule GLP-1 receptor agonists.
Conclusions:
- GPCR-targeted therapies, particularly GLP-1RAs, are revolutionizing obesity treatment.
- The obesity market is expanding with innovative therapeutic approaches.
- Future treatments focus on combination therapies, oral formulations, and novel small molecules for enhanced efficacy and patient adherence.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
11:49Characterization of G Protein-coupled Receptors by a Fluorescence-based Calcium Mobilization Assay
Published on: July 28, 2014
Related Concept Videos
G-protein Coupled Receptors
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Transducer Mechanism: G Protein–Coupled Receptors
GPCRs are also called heptahelical,...
GPCRs Regulate Adenylyl Cylase Activity
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Activation and Inactivation of G Proteins